BCM
ADVM

Burrage Capital Management’s Adverum Biotechnologies ADVM Stock Holding History

Burrage Capital Management’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-15,601
Closed -$3.26M – 28
2020
Q2 		$3.26M Hold
15,601
– – 2.28% 21
2020
Q1 		$1.56M Buy
15,601
+12,421
+391% +$1.45M 1.53% 24
2019
Q4 		$366K Buy
+3,180
New +$280K 0.25% 25

Other funds holding ADVM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Burrage Capital Management's ADVM Position: Q3 2020 in Review

Burrage Capital Management sold out of Adverum Biotechnologies (ADVM) in Q3 2020, closing a stake of 15,601 shares — an estimated $3.26M sold.

Burrage Capital Management first reported a position in ADVM in Q4 2019 and held it in 3 quarters. The position peaked at $3.26M in Q2 2020. 160 funds tracked by Wall St. Rank hold ADVM as of Q3 2020.

  • Burrage Capital Management reported no remaining Adverum Biotechnologies position as of Q3 2020 after selling out during the quarter.
  • Burrage Capital Management sold 15,601 Adverum Biotechnologies shares in Q3 2020, an estimated $3.26M.
  • Burrage Capital Management first reported a position in Adverum Biotechnologies in Q4 2019 and held it in 3 quarters.
  • Burrage Capital Management's Adverum Biotechnologies position peaked at $3.26M in Q2 2020.
  • 160 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q3 2020.

Based on Burrage Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.